Lilly Collaborates with AC Immune (AC) to Develop Candidates for Neurodegenerative Diseases
Shots:
- AC Immune to receive $80M upfront- $1760M milestones and royalties on sales and Lilly to get WW commercialization rights for AC Immune’s tau aggregation inhibitors and will invest $50M as convertible notes in AC. AC to initiate P-I study for Morphomer inhibitors and Lilly to fund the trial
- The focus of the agreement is to develop AC Immune's candidate- ACI-302 by combining AC Immune's Morphomer technology with Lilly’s development technology
- Morphomer inhibitors are indicated for reduction of toxic intracellular misfolded and aggregated tau indicated for Alzheimer's disease (AD) and multiple neurodegenerative diseases
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
